Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Pharma Simcere Files IND For Humanized Rabbit Monoclonal Antibody

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - Chinese drug manufacturer and distributor Simcere Pharmaceutical Group filed an investigational new drug application earlier this month with China's State FDA to launch a Phase I trial of APX003, a novel humanized rabbit monoclonal antibody to treat solid-tumor cancer

You may also be interested in...



Deals Of The Week: Mersana/Endo, Nuron/Akshaya, Array BioPharma/Foundation Medicine

The Domain Associates/Rusnano tie-up looks new on the surface, but is driven by a familiar imperative – the need to find new funding streams for biotechs still working to build up their exit value.

With Government Support, China Medical City Looks To Separate Itself From The Pack

NEW YORK - Perhaps the largest hurdle China Medical City faces with a U.S. audience is explaining how it differs from China's more established science and technology parks like Zhangjiang Hi Tech Park in Shanghai, Zhong-guan-cun Life Science Park in Beijing and BioBay in Suzhou

With Government Support, China Medical City Looks To Separate Itself From The Pack

NEW YORK - Perhaps the largest hurdle China Medical City faces with a U.S. audience is explaining how it differs from China's more established science and technology parks like Zhangjiang Hi Tech Park in Shanghai, Zhong-guan-cun Life Science Park in Beijing and BioBay in Suzhou

Related Content

UsernamePublicRestriction

Register

SC077448

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel